 NEW YORK, Dec. 28, 2020 GLOBE NEWSWIRE -- Y-mAbs Therapeutics, Inc. the Company or Y-mAbs Nasdaq: YMAB a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that it has entered into a definitive agreement to sell its Priority Review Voucher PRV to United Therapeutics Corporation Nasdaq: UTHR, based on an agreed valuation of 105 million. 